Sundrug: long-term performance & turning pointsSales (revenue) and profit-margin ratio
Sales (¥ bn)Net margin (%)
1957From a Setagaya pharmacy to a suburban chain
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
1957Yukimasa Tada opens the Futaba Pharmacy in Setagaya, Tokyo — five tsubo (about 16 m²)
1965Reorganized as Sundrug Ltd.; the chain begins
1980Incorporated as Sundrug Co., Ltd.; first suburban drugstore opens in Hachioji
Sundrug began in December 1957 as a single five-tsubo pharmacy — barely sixteen square metres — that Yukimasa Tada opened in the Chitose-Funabashi district of Setagaya, Tokyo, and named the Futaba Pharmacy. Drug retailing in post-war Japan was overwhelmingly a corner-shop trade: individual apothecaries, almost none of them running more than one store. Tada, born in 1927, set out to build something larger, and in April 1965 reorganized the business as Sundrug Ltd., beginning — from that base — to open a chain.
In July 1980 the limited company was recast as a joint-stock corporation, Sundrug Co., Ltd., and that December it opened a suburban drugstore in Hachioji, on Tokyo’s western fringe. The move away from the shopping-street pharmacy toward a car-oriented, American-style format — a parking lot out front, medicines, cosmetics and daily goods stacked in volume — set the template Sundrug would run on for decades. Twenty-three years after its founding, the corner apothecary had become a multi-store chain, still led by the founder, who would hold the presidency until 1994.
1986Automated-picking distribution centre opens in Kunitachi, Tokyo
1987Head office relocates to Fuchu, Tokyo
1991POS registers installed across all stores
What set Sundrug apart was not a product but a cost structure, and it was built early. From February 1985 the company put its sales and ordering on line; in December 1986 it opened a distribution centre with an automated picking system in Kunitachi; and by November 1991 it had installed point-of-sale registers across every store. Full computer systems were not yet common in the drugstore trade, and for a chain of this size to invest ahead of the field — while the founder still ran it — was unusual.
The pay-off was structural. Logistics and POS let Sundrug hold its labour and overhead ratios well below the industry norm, and that discipline, more than any single store, is the source of the low selling-and-administrative-expense ratio the company became known for. A drugstore earns by pairing high-margin medicines with low-margin food and sundries; Sundrug supported that arithmetic with its systems, lifting turnover per store until even loss-leader pricing paid. By the early 1990s single-company sales had reached about $206.9M (¥23bn), and the cost machine that would carry the next two decades was essentially in place — ready for a public listing.
1994Shares registered over the counter; Tatsuro Saizu becomes president
1997Listed on the Tokyo Stock Exchange (Second Section)
2002Promoted to the TSE First Section
2009Acquires the Direx discount chain — a second format
2013Motoya Akao succeeds Saizu as president
2018Akao dies in office; Saizu returns as interim president
In August 1994 Sundrug registered its shares over the counter, and in the same year the founder handed the presidency to Tatsuro Saizu, an executive vice-president and the first leader from outside the founding family. Saizu inherited consolidated sales of about $272.9M (¥28bn) and, by the time he moved up to chairman in 2013, had multiplied them roughly sixteen-fold to about $4.2B (¥448bn), with operating profit up more than twelvefold. The twenty consecutive years of rising sales and profit that opened his tenure became a record spoken of across Japanese retail.
The growth had two engines. One was a roll-up of regional operators — Taisei Home Aid in Chiba (1996), then chains in Tochigi, Kanagawa, Niigata, Aichi and Hokkaido — knitted together through franchising and acquisition rather than imposed from head office, so that Sundrug spread nationwide by networking local businesses. The other was the low-cost operation itself, layered on the 1980s logistics and POS base: the company held its selling-and-administrative ratio under 20% and, by 2009, posted an ordinary-profit margin of 6.5%.
The larger strategic move came in December 2009, when Sundrug bought Direx — a discount-store chain across Kyushu and the Chugoku-Shikoku region, with annual sales near $958M (¥90bn) — for about $101.6M (¥10bn). Direx’s strength in fresh food and large suburban stores let Sundrug split its map: drugstores for dense city markets, fresh-food discount stores for thinner rural ones. The purchase turned Sundrug into a two-format company. Succession, though, grew turbulent — Saizu passed the presidency to Motoya Akao in 2013, but Akao died in office in 2018, forcing Saizu to hold the post again until Koji Sadakata took over in May 2019.
2024Takes a 33.4% stake in Kirindo Holdings — an equity-method affiliate
Koji Sadakata took the presidency in 2019 as the drugstore trade entered a decade of mergers. In October 2021 Matsumotokiyoshi and Cocokara Fine combined into Matsukiyo Cocokara & Company, with sales of about $9.1B (¥1tn); in February 2024 Welcia and Tsuruha announced a tie-up aimed at roughly $13.2B (¥2tn) by the end of 2027. Sundrug, with consolidated sales near $5.4B (¥802bn) in the year to March 2025, sat apart from these giants.
Rather than merge, Sadakata chose a middle path — his own store openings plus loose capital alliances. In November 2023 Sundrug signed a capital tie-up with BCPE Knight Holdings Cayman, and in February 2024 it took an indirect 33.4% stake in Kansai-based Kirindo Holdings, making it an equity-method affiliate. Keeping Kirindo — whose store territory barely overlaps Sundrug’s — at an equity stake rather than a full takeover was deliberate: preserve each side’s independence while cooperating on private-label development, and signal no rush to consolidate.
Sundrug’s medium-term plan targets $6.3B (¥1tn) in sales and 1,750 stores by March 2026 — a steep reach that organic growth alone will not close, to be bridged by deeper cooperation with Kirindo and further acquisitions. Yet the discipline holds: the year to March 2025 marked a twenty-third straight annual dividend increase, and net profit had risen two-and-a-half-fold over the prior thirteen years — grown, in Sundrug’s fashion, by widening profit itself rather than by paying out a larger share. The cost-first, high-margin model that Tatsuro Saizu hardened has carried into Sadakata’s independent, mid-sized course through a consolidating trade.
The turning points, read in full: what was at stake, what was chosen and what the revenue did around it. The complete sourced record of each — background, options weighed, outcome — is in the Japanese edition, linked under every decision.
Revenue (¥ bn) · net margin % · around FY2009
Key decision · 2009
The Direx acquisition: a second format (2009)
Covering the ground your strength cannot reach, with a different format
The heart of this acquisition lies in filling the space outside the trade area where its own drugstores work best — with a format of a different character. The low-cost store Sundrug had honed in cities and their suburbs is hard to run profitably if simply stretched out into thinly populated country. Rather than fill that blank with stores of its own, Sundrug swallowed whole a company that held a different answer: a discount store carrying goods down to fresh food. Sharing the same foundation of low-cost management, but using two formats according to differences of customer and location — the founding generation’s fixation on the trade area can be seen coming to fruition in the shape of a twin-format business.
That said, while the two-format shape pushes up scale, it also carries the difficulty of running businesses of different character inside one company. A discount store, weighted toward food and fresh produce, earns a thinner gross margin than a drugstore built around medicines and cosmetics, and rising sales do not necessarily lift the profit rate in step. As the industry moved toward trillion-yen combinations like Matsukiyo Cocokara and Welcia-Tsuruha, Sundrug stayed out of the large reorganizations, choosing its own path with two formats and loose alliances. How to keep binding the urban drugstore and the rural discount store together — the choice made in the 2009 acquisition is still being tested today.
An equity stake, not a takeover: partnering with Kirindo (2023)
Can independence and scale coexist?
The heart of this decision lies in deliberately avoiding full integration — choosing independence and complement — even as the majors bundled themselves into one- and two-trillion-yen alliances. Take a majority and you can consolidate the accounts, and your purchasing volume rises directly with it. Even so, President Sadakata held to a one-third stake and left the other side its autonomy. With a Kansai chain whose stores do not overlap his own, he would join forces on procurement and private-label development while each kept its independence. It was one answer to supplementing scale without being swallowed by the top alliances — a choice placed on the line of self-reliance running from Saizu’s day.
That said, the equity method carries limited influence, and it is harder to generate the procurement power of a full merger. The more independence you leave in place, the thinner the fruit that integration bears. Whether the gap to the $6.3B (¥1tn) sales target can be closed by this alliance and further M&A alone is not yet clear. In an industry where the majors assemble two-trillion-yen alliances, how is a mid-sized player to reconcile independence with scale? The equity-method partnership with Kirindo leaves that question open.
The low-cost, high-margin model — and twenty straight years of growth (1994)
Running an unglamorous formula, for a very long time
The heart of this decision lies in a second-generation leader from outside the founding family running one unglamorous formula for a very long time. What Saizu brought was neither a new product nor a new market, but a thoroughness of plain operation: confine locations to residential and suburban sites, pare costs to the bone, and raise the strength of the sales floor by developing people. That he could flatly say retailing creates nothing new, and that turning a profit is therefore only to be expected, was surely because he believed profit is born not of luck or a booming economy but of the daily design of operations. The length — twenty straight years — shows that this conviction was no passing thing.
That said, marrying low cost to high profit has a hidden face. The refusal to yield on price in contested areas, and the hard terms imposed on wholesalers, were the reverse side of that efficiency. The larger the scale grows, the heavier the question of how far this formula can be preserved. In later years, in fact, Sundrug kept its distance from the industry’s large mergers, choosing its own path through the two-format shift with Direx and loose capital alliances. Amid a competition that chases scale, how to inherit the low-cost, high-margin formula Saizu honed — that question remains with the company now that the manager from outside the founding family has gone.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— Sundrug full history in Japanese →